Bli medlem
Bli medlem

Du är här


WntResearch: Preclinical toxicology studies for Foxy-5 are completed

WntResearch today announces that the Foxy-5 preclinical toxicology
studies in rats and dogs have been completed. No toxicities have been

The final toxicology studies for Foxy-5 in rats and dogs have been
completed. No adverse effects in either species have been observed
even at the highest doses applied. The only reported observation was
that male rats showed a slightly reduced body weight at the highest
dose, whereas this tendency was not seen in female rats or in dogs of
any sex. It is worth mentioning that the animals received Foxy-5
every day (duration 6 months for rats and 9 months for dogs) while
patients in the recently finalized clinical study (see press release
as of November 5) received Foxy-5 only three days a week.

CEO, Nils Brünner explains: "Our plan has been to combine Foxy-5 with
standard chemotherapy in order to hit the cancer cells from different
directions. These new data, together with the results from our
recently finalized clinical phase 1 study, make us confident that
Foxy-5 is a non-toxic compound. Hence, we will be able to combine
Foxy-5 with almost any type of chemotherapy and maybe even with newer
biological agents. I am very satisfied with these results and we are
looking forward to continue the exiting journey with Foxy-5 by
initiating the planned phase 1b study as soon as possible."

For additional information please contact:
Nils Brünner, CEO
Telephone: + 45 2614 4708

About WntResearch
WntResearch AB is a public company on the AktieTorget in Sweden.
WntResearch develops the anti-cancer compound Foxy-5 to be used to
combat the metastatic process of cancer. WntResearch has one drug
candidate in clinical phase 1 - Foxy-5 - as well as one candidate
drug in preclinical development - Box-5. The Company is currently
focusing mainly on the development of Foxy-5.


Författare SIX news

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.